This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Xofigo Banner

About Xofigo
®
(radium-223 dichloride) In mCRPC

Patient Image - Xofigo

For adult patients with metastatic castration-resistant prostate cancer (mCRPC)

Xofigo (+ best standard of care) is the first targeted alpha therapy to improve overall survival and slow down the decline of quality of life during on treatment period vs placebo + best standard of care (BSC) in mCRPC patients with symptomatic bone metastases and no known visceral metastases.

Xofigo monotherapy or in combination with luteinising hormone releasing hormone (LHRH) analogue is indicated for the treatment of adult patients with mCRPC, symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment.

PP-XOF-IE-0127-1   |   January 2026

 

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.

    • 1
      Xofigo®(radium-223 dichloride): Summary of Product Characteristics.
    • 2
      Parker C, et al. Prostate Cancer Prostatic Dis. 2018;21(1):37-47.
    • 3
      Parker C, et al. N Engl J Med. 2013;369(3):213-223.
    • 4
      Nilsson S, et al. Ann Oncol. 2016;27(5):868-874.
    • 5
      Suominen MI, et al. Clin Cancer Res. 2017;23(15):4335-4346.
    • 6
      Nilsson S, et al. Ann Oncol. 2016;27(5):868-874. Supplementary data.